Country for PR: United Kingdom
Contributor: PR Newswire Europe
Friday, September 14 2018 - 21:56
Experts Call for Improved Identification of 'High Burden' Rosacea Patients in Everyday Practice
PARIS, Sept. 14, 2018 /PRNewswire-AsiaNet/ --

    Additional analysis of global survey data reveals quality of life is 
impacted by several factors extending beyond severity of rosacea alone

    Additional analysis of a global survey conducted and presented earlier this 
year, as an expert-authored report called 'Rosacea: Beyond the visible',[ ] assists healthcare 
professionals (HCPs) to identify the common characteristics of High Burden* 
(HB) rosacea patients. Results of the analysis have the aim of increasing 
tailored treatment regimens to improve patient care. Results presented during a 
symposium at the 27th European Academy of Dermatology and Venerology (EADV) 
Congress in Paris, France, yesterday, reveal that a broader definition of HB 
patients is needed to help reduce burden in daily practice.

(Logo: )

    The data analysis classified HB patients based on how severely their 
condition impacts their quality of life (QoL), the extent to which it 
influences their behavior and their level of desire for a cure.[1]

    "People with rosacea are often judged on their appearance, which impacts 
them greatly in daily life. If their rosacea is severe, the symptoms are likely 
to be more significant also, from itching and burning to a permanently red 
central facial area. However, even people with less severe rosacea report a 
significant impact on quality of life, which suggests that assessing patients 
on clinical severity alone is not enough," said Prof. Dr. Uwe Gieler, Dept. of 
Dermatology and Clinic of Psychosomatic Medicine and Psychotherapy, 
Justus-Liebig-University of Giessen, Germany and one of the authors of the 
Rosacea: Beyond the visible report. "By improving identification of this 
demographic, dermatologists and other healthcare professionals will be better 
equipped to tailor treatment to the individual's needs and ultimately improve 
care for people living with this chronic skin disease."

    The data revealed HB rosacea patients were significantly younger, employed 
and more likely to be male, compared to their less HB peers. Another 
characteristic defined included an increase in skin sensations (such as itching 
48% vs 37% and pain 23% vs 13%) in comparison with their less HB peers over the 
last 12 months.

    HB risk is affected by severity of symptoms; however, this state can be 
associated with any severity of rosacea. When looking over 12 months, HB 
patients were shown to have a significant increase in risk of experiencing an 
impact on daily activities, such as their skin care regime, as well as 
experiencing discomfort due to their disease when compared to non-HB patients. 
Other risk-factors included; a family history of rosacea and an increase of 
rosacea-related Emergency Rooms visits.

    Experts concluded that healthcare professionals treating rosacea patients 
should include questions relating to burden in everyday practice, to ensure 
treatment is aligned with patients' disease experience, not just disease 

    The presentation is titled "Defining High Burden patients" (Gieler, U. et 
al., 27th European Academy of Dermatology and Venerology (EADV) Congress, 13 
September 2018).

    *Patients were categorized as high burden (HB) when at least three of four 
domains were positive (threshold defined by the cohort median).

    Domain                   Proxy question                    Positive 
    QoL                      Overall impact on QoL (0-10)      Score >5
                             Level of behavioral adaptation
    Lifestyle                (0-10)                            Score >6
                             Willingness to pay to obtain a
    Economic                 complete cure                     >20% of monthly 
                             Willingness to trade years of
    Psychosocial/emotional   life for a complete cure          >6 months

    For related multimedia resources, please visit

    About Rosacea   

    Rosacea is a common inflammatory skin disease that presents variable 
clinical characteristics, of which the most common are flushing, permanent 
erythema, and inflammatory lesions. It mainly affects the central areas of the 
face, such as the cheeks and nose. The disease can affect both adult men and 
women, usually after the age of 30. Additionally, symptoms such as stinging, 
burning and increased sensitivity of the skin are common. The eyes are often 
affected, and might present as red, dry or itchy.

    Although the cause of the disease is still under debate, various trigger 
factors are known, including spicy foods, alcohol, emotional stress, 
sun/UV-exposure, hot baths and beverages. Demodex, generally harmless mites, 
can also be found in the skin in an elevated quantity in people with rosacea.

    Rosacea may worsen over time if left untreated. People that suspect they 
suffer from rosacea should visit their dermatologist or healthcare provider for 
diagnosis and discuss what treatment is right for them. Because rosacea is a 
highly visible disease, it is known to cause embarrassment and anxiety in some 
patients, which in turn may cause frustration and have a negative impact on 
their social life.

    About the BURDEN survey   

    The BURDEN survey was developed by Kantar Health as a self-administered 
online survey and supported by Galderma. The survey involved 710 patients 
diagnosed with rosacea and 554 dermatologists and general practitioners (GPs) 
in 6 different countries (France, Germany, Italy, UK, Canada and the US). The 
survey asked respondents about their experience of living with, or treating 
patients that are living with, rosacea.

    Participants were recruited using the Kantar online panel. To maximize the 
sample size no quota was set up. Therefore, the sample is not representative of 
the rosacea population of each country; consequently, the results of this study 
could be affected by selection bias and cannot be inferred to the whole rosacea 

    About Galderma  

    Galderma, Nestlé Skin Health's medical solutions business, was created in 
1981 and is now present in over 100 countries with an extensive product 
portfolio to treat a range of dermatological conditions. The company partners 
with health care practitioners around the world to meet the skin health needs 
of people throughout their lifetime. Galderma is a leader in research and 
development of scientifically-defined and medically-proven solutions for the 
skin. For more information, please visit


    1. Galderma data on file.

SOURCE: Galderma